Results 51 to 60 of about 53,405 (189)
Genetic Analysis of Imatinib Resistance in CML: The Role of T315I and E255K
Advances in Hematology, Volume 2026, Issue 1, 2026.Background and Aims Imatinib mesylate is a small molecule inhibitor targeting the BCR‐ABL tyrosine kinase. However, some CML patients develop resistance to imatinib. This resistance is commonly associated with mutations in the kinase domain of BCR‐ABL, notably the prevalent T315I and E255K mutations.
Saba Yari +4 more
wiley +1 more source
Imatinib resistance: diagnostic and therapeutic choices
Clinical Management Issues, 2015 We report a case of a 42-year-old woman with t(9;22) positive chronic myeloid leukemia (CML) who developed a sub-optimal response to therapy with imatinib mesylate due to M351T mutation and low plasma level of imatinib. Dose increase of imatinib resulted
Marianna De Muro +3 more
doaj +1 more source
Impact of Imatinib Therapy on Immunometabolism to Promote β‐Cell Survival in Diabetes
Journal of Diabetes, Volume 18, Issue 7, July 2026.
Sandeep Kumar, Reena Kumari
wiley +1 more source
International Journal of Endocrinology, Volume 2026, Issue 1, 2026.Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang +6 more
wiley +1 more source
XML Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
Iranian Journal of Blood and Cancer, 2016 Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML).
Abolghasem Allahyari +3 more
doaj
Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
Acta Medica Alanya, 2020 Aim: Imatinib mesylate is a tyrosine kinase inhibitor and is approved as a standard first-line therapy of chronic myeloid leukemia. Oxidative stress, as well as intracellular calcium overload and mitochondrial dysfunction, play an important role in ...
İshak Suat Övey, Can Ramazan Öncel
doaj
Ageing is a risk factor in imatinib mesylate cardiotoxicity
European Journal of Heart Failure, 2014 Chemotherapy‐induced heart failure is increasingly recognized as a major clinical challenge. Cardiotoxicity of imatinib mesylate, a highly selective and effective anticancer drug belonging to the new class of tyrosine kinase inhibitors, is being reported
Wael M Maharsy +4 more
semanticscholar +1 more source
Journal of Diabetes Research, Volume 2026, Issue 1, 2026.Background Diabetic atrial cardiomyopathy, a component of diabetic cardiomyopathy, is increasingly recognized. However, atrial‐focused mechanistic and clinical frameworks remain less developed than ventricular paradigms. Main Body This review synthesizes the pathogenesis of diabetic atrial cardiomyopathy from conventional, multiomics, and translational
Helin Yang +3 more
wiley +1 more source
Imatinib and hypophosphatemia: Case report and review of literature
Journal of Oncological Sciences, 2017 Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated.
Erdem Şen, İrem Öner, Özlem Ata
doaj +1 more source
Molecular Cancer Therapeutics, 2014 Gastrointestinal stromal tumor (GIST) is a rare and therefore often neglected disease. Introduction of the kinase inhibitor imatinib mesylate radically improved the clinical response of patients with GIST; however, its effects are often short-lived, with
Ziyan Y. Pessetto +5 more
semanticscholar +1 more source